Fidaxomicin denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for fidaxomicin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Fidaxomicin as "Not FDA-Approved"

Fidaxomicin is FDA-approved for the treatment of Clostridioides difficile infection (CDI) in adults and pediatric patients. A denial from UnitedHealthcare classifying fidaxomicin as "not FDA-approved" is inconsistent with the drug's regulatory status for its approved indication and warrants immediate challenge. This type of denial most commonly reflects a system error — a claim coding issue, a formulary database lag, or the drug being processed under an incorrect billing code — rather than an accurate clinical or regulatory determination.

Less commonly, the denial may refer to an off-label use (for example, prophylaxis or a patient population outside the approved label). If the use is off-label, the appeal strategy shifts to demonstrating compendia or guideline organization support.

## Why This Denial Is Appealable

An insurer may not deny coverage of an FDA-approved drug for its approved indication on the basis that it is not FDA-approved. This is a factual error, and the appeal letter should lead with that fact directly and attach the prescribing label as primary evidence. For on-label use, this type of denial is among the most straightforward to reverse at the internal appeal stage.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 or ACA §2719 within the deadline on your Explanation of Benefits. Request the specific documentation UHC relied on to conclude the drug lacks FDA approval.
• External review: After an adverse internal decision, request IRO review within approximately four months. The IRO will have access to the same FDA approval records.
• Expedited review: CDI is an acute condition. Request expedited processing with a physician letter documenting urgent clinical need.

## Documentation to Gather

• FDA prescribing label: A current copy of the FDA-approved fidaxomicin prescribing label, showing the approval date and the approved indication(s). This is the single most important exhibit.
• Diagnosis confirmation: Lab-confirmed CDI diagnosis, confirming the drug is being used for an approved indication.
• Billing/coding records: Confirm the claim was submitted with the correct NDC (National Drug Code) and diagnosis codes. A coding mismatch is the most common cause of erroneous "not approved" flags.
• Prescriber medical-necessity letter: A brief letter from the treating physician confirming on-label use and citing the FDA-approved indication.
• UHC's denial rationale: Request the full written denial rationale and the specific policy section or evidence base UHC used. This is required to be provided under ERISA and the ACA.

## Criteria-Mapping Structure

| UHC Denial Basis | Source | Rebuttal Evidence | |---|---|---| | [UHC's stated basis for the "not approved" determination] | [Denial letter / policy section] | [FDA approval date, label exhibit, NDC code] |

The appeal letter should open with a clear, factual statement: fidaxomicin received FDA approval for CDI, the prescribing label (attached as Exhibit A) confirms this, and the patient's use is on-label as confirmed by the attached lab results and physician letter. Keep the letter concise and evidence-forward.